Product in Development
Total Payments
$42.1M
Transactions
13,443
Doctors
953
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $4.5M | 1,672 | 211 |
| 2023 | $4.2M | 1,489 | 163 |
| 2022 | $4.0M | 1,360 | 110 |
| 2021 | $4.1M | 1,502 | 139 |
| 2020 | $5.0M | 1,587 | 255 |
| 2019 | $6.5M | 2,087 | 265 |
| 2018 | $6.5M | 2,234 | 272 |
| 2017 | $7.2M | 1,512 | 327 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $32.8M | 7,162 | 78.0% |
| Consulting Fee | $7.7M | 2,549 | 18.3% |
| Travel and Lodging | $515,431 | 1,230 | 1.2% |
| Honoraria | $470,878 | 221 | 1.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $431,746 | 28 | 1.0% |
| Food and Beverage | $128,052 | 2,249 | 0.3% |
| Royalty or License | $12,563 | 2 | 0.0% |
| Education | $1,835 | 2 | 0.0% |
Payments by Type
Research
$32.8M
7,162 transactions
General
$9.3M
6,281 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Evaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms | W. L. Gore & Associates, Inc. | $4.4M | 0 |
| GORE CARDIOFORM ASD Occluder Clinical Study: A Study to evaluate safety and efficacy in the treatment of transcatheter closure of ostium secundum atrial septal defects (ASDs) | W. L. Gore & Associates, Inc. | $4.1M | 0 |
| Evaluation of the GORE TAG Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta | W. L. Gore & Associates, Inc. | $4.1M | 0 |
| CSL112_3001 | CSL Behring | $2.0M | 0 |
| GREAT Global Registry for Endovascular Aortic Treatment | W. L. Gore & Associates, Inc. | $1.9M | 0 |
| GORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale (PFO): the REDUCE Post Approval Study | W. L. Gore & Associates, Inc. | $1.8M | 0 |
| GORE EXCLUDER Conformable Endoprosthesis | W. L. Gore & Associates, Inc. | $1.8M | 0 |
| Evaluation of the GORE TAG TSSB-LSA Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms | W. L. Gore & Associates, Inc. | $1.3M | 0 |
| Evaluation of the GORE Ascending Stent Graft in the Treatment of Isolated Lesions, Pseudoaneurysms, and Penetrating Aortic Ulcers of Ascending Aorta and Aortic Arch | W. L. Gore & Associates, Inc. | $817,551 | 0 |
| GORE CARDIOFORM Septal Occluder Migraine Clinical Study: A Study to evaluate the safety and efficacy of transcatheter closure of patent foramen ovale for relief of migraine headaches | W. L. Gore & Associates, Inc. | $810,184 | 0 |
| GORE EXCLUDERConformable Endoprosthesis | W. L. Gore & Associates, Inc. | $771,924 | 0 |
| TAMBE - Initial Feasibility Assessment of the GORE EXCLUDER Juxtarenal and Thoracoabcominal Branch System in the Treatment of Crawford Type IV Thoracoabdomial and Juxtarenal Aortic Aneurysms | W. L. Gore & Associates, Inc. | $708,617 | 0 |
| Gore Research and Development | W. L. Gore & Associates, Inc. | $638,949 | 0 |
| GORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale PFO the REDUCE Post Approval Study | W. L. Gore & Associates, Inc. | $538,972 | 0 |
| Evaluation of the GORE TAG TSSB-BCA Endoprosthesis in the Treatment of Aortic Arch Aneurysms | W. L. Gore & Associates, Inc. | $524,379 | 0 |
| Evaluation of the GORE EXCLUDER Iliac Branch Endoprosthesis for the Treatment of Common Iliac Artery Aneurysms or Aorto-iliac Aneurysms | W. L. Gore & Associates, Inc. | $495,383 | 0 |
| GORE SYNECOR Study: A study to evaluate mid-term performance in the treatment of ventral, incisional, parastomal, and inguinal hernias | W. L. Gore & Associates, Inc. | $493,076 | 0 |
| Evaluation of the GORE TAG TSSB LSA Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms | W. L. Gore & Associates, Inc. | $453,716 | 0 |
| A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction | CSL Behring | $444,190 | 0 |
| GORE ENFORM Biomaterial Product Study: A study to describe biomaterial multi-use performance | W. L. Gore & Associates, Inc. | $354,366 | 0 |
Top Doctors Receiving Payments for Product in Development — Page 39
Ad
Manufacturing Companies
- W. L. Gore & Associates, Inc. $38.0M
- CSL Behring $4.1M
- DENTSPLY DeTrey GmbH $48,407
- Roche Diagnostics Corporation $1,200
- Dentsply Sirona Inc $32.52
Product Information
- Type Device
- Total Payments $42.1M
- Total Doctors 953
- Transactions 13,443
About Product in Development
Product in Development is a device associated with $42.1M in payments to 953 healthcare providers, recorded across 13,443 transactions in the CMS Open Payments database. The primary manufacturer is W. L. Gore & Associates, Inc..
Payment data is available from 2017 to 2024. In 2024, $4.5M was paid across 1,672 transactions to 211 doctors.
The most common payment nature for Product in Development is "Unspecified" ($32.8M, 78.0% of total).
Product in Development is associated with 20 research studies, including "Evaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms" ($4.4M).